Norwegian drug maker Algeta ASA, which set up a US commercial office in Cambridge last September, won Food and Drug Administration approval Wednesday to sell a new treatment in the United States for prostate cancer that has spread to the bones.
Algeta’s drug, called Xofigo, treats castration-resistant prostate cancer, a disease that afflicts tens of thousands of men in the United States and many more worldwide. The drug works by releasing targeted alpha-particle-emitting radiation into bones, killing cancer cells but doing limited damage to surrounding normal tissue, extending the lives of patients.
“In the long term, what we’re trying to do is improve the patients’ quality of life,” said Jeff Albers, the Cambridge-based president of the company’s Algeta US division. Full story for BostonGlobe.com subscribers.